STILNOCT

This brand name is authorized in Finland, Ireland, Netherlands, UK.

Active ingredients

The drug STILNOCT contains one active pharmaceutical ingredient (API):

1	Zolpidem UNII WY6W63843K - ZOLPIDEM TARTRATE
	Zolpidem is an imidazopyridine which preferentially binds the omega-1 receptor subtype (also known as the benzodiazepine-1 subtype) which corresponds to GABA-A receptors containing the alpha-1 sub-unit, whereas benzodiazepines non-selectively bind both omega-1 and omega-2 subtypes. The modulation of the chloride anion channel via this receptor leads to the specific sedative effects demonstrated by zolpidem. These effects are reversed by the benzodiazepine antagonist flumazenil.
	Read more about Zolpidem

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
STILNOCT Coated tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N05CF02	Zolpidem	N Nervous system → N05 Psycholeptics → N05C Hypnotics and sedatives → N05CF Benzodiazepine related drugs
Discover more medicines within N05CF02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
FI	Lääkealan turvallisuus- ja kehittämiskeskus	380694, 450734, 450775, 562556
GB	Medicines & Healthcare Products Regulatory Agency	31999
IE	Health Products Regulatory Authority	61188, 62701, 62702, 62741, 62755, 62756
NL	Z-Index G-Standaard, PRK	195995